Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/613656


Netherlands Pharmaceuticals and Healthcare Report Q2 2008


Description: The Netherlands Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Netherlands pharmaceuticals and healthcare industry.

Growth will be far from impressive for the drug market in the Netherlands over the forecast period, although, in many ways this reflects the general sluggishness seen in mature markets. BMI expects the market to reach a value of US$7.06bn in 2012, representing a compound annual growth rate (CAGR) of
2.08%. Growth will be strongest in the generics market but should also be reasonable for consumer health products as these medicines benefit from government liberalisation policies.

The generics sector, however, will be negatively impacted by the new transition agreement regarding pharmaceutical prices that has come into effect. In January 2008, the price of generic medicines was reduced by 10%. BMI has factored this decrease into our forecasts and believes that the generics market will reach a value of US$1.28bn by 2012. In addition, medicines whose patents expire in 2008 will see price cuts of 50%. The Dutch Pharmacy Association, KNMP, claims that the plans are designed to keep the cost of medicines down. Also, they are designed to help transform the pharmaceutical market from being supply-based to being demand-based.

In terms of company activity, the sector has been quiet after last year saw US drug-maker Schering-Plough acquire Organon, the pharmaceuticals division of Dutch industrial conglomerate Akzo Nobel for EUR11bn (US$14.5bn). However, in February 2008, a Dutch court ruled against US drug-maker Pfizer in a court case regarding the patent on atorvastatin, the key ingredient in cholesterol reducing drug Lipitor is invalid. This is a severe blow for Pfizer, as it could open the door for generic competition for its bestselling drug.

Meanwhile, recent attacks by animal extremists in the Netherlands have forced a local company to pull out of a life sciences project. BMI believes that the latest problems in the Netherlands, if sustained, will have a negative impact on the countrys Business Environment Rating. The Netherlands has a respected regulatory system, with an average score of eight across our three main indicators, but we will downgrade the scores if intimidation of the research sector is permitted to continue.


Contents: Executive Summary
Netherlands Pharmaceuticals And Healthcare Industry
Pharmaceutical Business Environment Ratings
Table: Western European Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement
OTC Medicines
Industry Developments
Healthcare Sector
Healthcare Insurance
Table: Key Points - Dutch Health Insurance Act, January 1 2006
Health Profile
Pharmaceuticals Sector
Recent Domestic Companies’ Activities
Recent Foreign Companies’ Activities
Research And Development Sector
Industry Forecast Scenario
Overall Market Forecast
Table: The Netherlands Drug Market Forecast Indicators
Key Growth Factors - Industry
Table: Netherlands Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Netherlands - Macroeconomic Forecasts
Patented Market Forecast
Table: The Netherlands’ Patented Drug Market Forecast Indicators (US$mn unless otherwise stated)
Over-The-Counter Market Forecast
Table: The Netherlands OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics Forecasts
Table: The Netherlands’ Generics And Branded Market Forecast Indicators
Export/Import Forecasts
Table: The Netherlands’ Pharmaceutical Trade Forecast Indicators (US$mn)
Key Risks To our Forecast Scenario
Competitive Landscape

Company Profiles

Leading Multinational Manufacturers
- Merck & Co
- Pfizer
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Novartis

Indigenous Manufacturers
- Akzo Nobel
- DSM
- Qiagen
- Pharming Group
- Crucell

BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources



Companies Mentioned - Merck & Co - Pfizer - GlaxoSmithKline (GSK) - Sanofi-Aventis - Novartis - Akzo Nobel - DSM - Qiagen - Pharming Group - Crucell


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/613656

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 16/02/2012 21:44:13
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Netherlands Pharmaceuticals and Healthcare Report Q2 2008
Web Address:
http://www.researchandmarkets.com/reports/613656
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €393.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 16/02/2012 21:44:13

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)